Professor & Executive Dean for Clinical Affairs
Henry Ford Health System

Printed as of 11/21/2024

Disclosures

Personal Commercial (5)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------|---------------------------|--------------------------|-------------------------------------|
| Self | | | |
| Abbott | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| abiomed | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Boston Scientific | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| Edwards lifesciences | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| Medtronic | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------------------|---------------------------|--------------------|-------------------------------------|
| Self | | | |
| Medtronics | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |

Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------|---------------|----------------------|
| surtavi | MEDTRONIC | MEDTRONIC |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

| Year | Case Title | Represented | Description | Compensation |
|------|------------------------|-------------------------|---|--------------------|
| Self | | | | |
| 2019 | PCI appropriateness | Defendant † Doctors LLC | I reviewed a decsion by a hosptial MEC to remove priviedges for PCI from a physician in Petoskey Michigan | Modest (< \$5,000) |
| 2010 | maryland board hearing | Defendant | I testified for Dr Mark Midei in his efforts to retain a license to practice in medicine in Maryland. | None (\$0) |
| | | | | |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 3/9/2021

 $\textit{URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement agreement$

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/9/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 3/9/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/9/2021

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.